Pharming released from CSL Behring court case
Other updatesCSL Behring and Pharming have mutually agreed that CSL will dismiss Pharming from the case against Dr. Chiao.
Pharming responds to press speculation
Other updatesPharming Group N.V. today confirmed it has been included in an injunction in the US obtained by CSL Behring, a subsidiary of CSL Limited of Australia (“CSL”), to prevent possible transmission of proprietary documents and data to Pharming which CSL claims have been removed from its systems by Dr Joseph Chiao, who was hired recently by Pharming to be a medical director.
Sijmen de Vries presents at H.C. Wainwright Conference in NY
Conference attendanceCEO of Pharming Sijmen de Vries presented at the 21st Annual Global Life Science Investment Conference on the 9th of September in New York City.
Pharming acquires exclusive license to CDZ173, a late stage drug for the treatment of APDS
Operational updatesPharming Group N.V. announces it has entered into a development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome (“APDS”).
Pharming Reports on Financial Results for the First Half of 2019
Financial updatesPharming Group N.V. presents its (unaudited) interim financial report for the first half year ended 30 June 2019.
Pharming Group: Halfjaarcijfers 2019
Financial updatesPharming Webinar: halfjaarcijfers 2019 donderdag 25 juli 2019 tussen 19.00 en 20.00 uur. Nu aanmelden!
Pharming announces initiation of clinical phase I/II pre-eclampsia study
Clinical trialsPharming Group N.V. today announces that, following receipt of the Dutch investigating centre’s ethics committee approval, it is commencing a clinical study of the effects of its recombinant human C1 esterase inhibitor (rhC1INH), RUCONEST®, in patients with pre-eclampsia
Pharming Reports on Annual General Meeting of Shareholders
Financial updatesPharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved. The presentation slides from today’s AGM are available on the Company’s website.
Pharming today celebrates “hae day :-)” – the global awareness day for hereditary angioedema, a rare life-threatening condition.
Other updatesOn 16 May each year, hereditary angioedema (HAE) patient organizations from around the world, led by the HAEi, the international umbrella organization for the world’s HAE patient groups, come together to support awareness of HAE; a rare, potentially life-threatening condition. hae day :-) aims to raise global awareness to ensure each and every patient receives faster diagnosis and the care they need to lead a better life.
Pharming Group reports interim financial results for the first quarter of 2019
Financial updatesPharming Group N.V. presents its (unaudited) interim financial report for the first quarter ended 31 March 2019.